Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?

Bibliography

• Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006;367:346-55
   PubMed Web of Science ®Google Scholar
• Van Houdenhove B, Luyten, P. Fibromyalgia and related syndromes characterised by stress intolerance and pain hypersensitivity: do we need a new nosology? Curr Rheumatol Rev 2007;3:304-8
   Google Scholar
• Jason LA, Helgerson J, Torres-Harding SR, Variability in diagnostic criteria for chronic fatigue syndrome may result in substantial differences in patterns of symptoms and disability. Eval Health Prof 2003;26:3-22
   PubMed Web of Science ®Google Scholar
• Fukuda K, Straus SE, Hickie I, The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953-9
   PubMed Web of Science ®Google Scholar
• Van Houdenhove B, Luyten P. Customizing treatment in chronic fatigue syndrome / fibromyalgia: the role of perpetuating factors. Psychosomatics 2008;45:470-7
   Google Scholar
• Pae C-U, Marks DM, Patkar AA, Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother 2009;10:1561-70
   PubMed Web of Science ®Google Scholar
• Bagnall A-M, Hempel S, Chambers D, The treatment and management of chronic fatigue syndrome (CFS) / myalgic encephalomyelitis (ME) in adults and children (CRD Report 35). York: University of York, 2007. Available from: http://www.york.ac.uk/inst/crd/CRD_Reports/crdreport35.pdf
   Google Scholar
• Belgian Health Care Knowledge Centre. Available from: http://www.kce.fgov.be/Download.aspx?ID=1222
   Google Scholar
• Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des 2008;14:1274-94
   PubMed Web of Science ®Google Scholar
• Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med 2006;119:167.e23-30
   Google Scholar
• Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006;37:139-50
   PubMed Web of Science ®Google Scholar
• White PD, Thomas JM, Kangro HO, Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet 2001;358:1946-54
   PubMed Web of Science ®Google Scholar
• Buchwald DS, Rea TD, Katon WJ, Acute infectious mononucleosis: characteristics of patients who report failure to recover. Am J Med 2000;109:531-7
   PubMed Web of Science ®Google Scholar
• Straus SE, Dale JK, Tobi M, Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. N Engl J Med 1988;319:1692-8
   PubMed Web of Science ®Google Scholar
• Lerner AM, Zervos M, Chang CH, A small, randomized, placebo-controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. Clin Infect Dis 2001;32:1657-8
   PubMedGoogle Scholar
• Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo 2007;21:707-13
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Turgonyi E, Kumar A, Clinical improvement in chronic fatigue syndrome is associated with enhanced natural killer cell-mediated cytotoxicity: the results of a pilot study with Isoprinosine. J Chronic Fatigue Syndr 2003;11:71-93
   Google Scholar
• Lorusso L, Mikhaylova SV, Capelli E, Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009;8:287-91
   PubMed Web of Science ®Google Scholar
• Steinberg P, McNutt BE, Marshall P, Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. J Allergy Clin Immunol 1996;97:119-26
   PubMed Web of Science ®Google Scholar
• Rowe KS. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. J Psychiatr Res 1997;31:133-47
   PubMed Web of Science ®Google Scholar
• Lloyd A, Hickie I, Wakefield D, Boughton CJD. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990;89:561-8
   PubMed Web of Science ®Google Scholar
• Peterson PK, Shepard J, Macres M, A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990;89:554-60
   PubMed Web of Science ®Google Scholar
• Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997;103:38-43
   PubMed Web of Science ®Google Scholar
• Brook MG, Bannister BA, Weir W. Interferon-alpha therapy for patients with chronic fatigue syndrome. J Infect Dis 1993;168:791-2
   PubMedGoogle Scholar
• See D, Tilles J. Alpha-Interferon treatment of patients with chronic fatigue syndrome. Immunol Invest 1996;25:153-64
   PubMed Web of Science ®Google Scholar
• Strayer DR, Carter WA, Brodsky I, A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18(Suppl 1):S88-95
   Google Scholar
• Lloyd A, Hickie I, Brockman A, Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203
   PubMed Web of Science ®Google Scholar
• Andersson M, Bagby JR, Dyrehag LCG. Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. Eur J Pain 1998;2:133-42
   PubMed Web of Science ®Google Scholar
• Zachrisson O, Regland B, Jahreskog M, Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome – a randomised controlled trial. Eur J Pain 2002;6:455-66
   PubMed Web of Science ®Google Scholar
• Nijs J, Nicolson GL, De Becker P, High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol 2002;34:209-14
   PubMed Web of Science ®Google Scholar
• Iwakami E, Arashima Y, Kato K, Treatment of chronic fatigue syndrome with antibiotics: pilot study assessing the involvement of coxiella burnetii infection. Intern Med 2005;44:1258-63
   PubMedGoogle Scholar
• Vermeulen RCW, Scholte HR. Azithromycin in chronic fatigue syndrome (CFS), an analysis of clinical data. J Transl Med 2006;4:34
   PubMedGoogle Scholar
• Endresen GK. Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes. Rheumatol Int 2003;23:211-5
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration, 2001. Available from: http://www.fda.gov/cder/drug/infopage/penG_doxy/QA_doxy.htm
   Google Scholar
• Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008;47:284-8
   PubMed Web of Science ®Google Scholar
• Donta ST, Engel CC Jr, Collins JF, Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:85-94
   PubMedGoogle Scholar
• Randall DC, Cafferty FH, Shneerson JM, Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005;19:647-60
   PubMed Web of Science ®Google Scholar
• Olson LG, Ambrogetti A, Sutherland DC. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. Psychosomatics 2003;44:38-43
   PubMed Web of Science ®Google Scholar
• Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009;301:198-209
   PubMed Web of Science ®Google Scholar
• Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry 2008;69(Suppl 2):6-13
   PubMedGoogle Scholar
• Dhir A, Kulkarni SK. Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. Pharmacol Biochem Behav 2008;89:563-71
   PubMed Web of Science ®Google Scholar
• Kumar A, Garg R. Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations. Fundam Clin Pharmacol 2009;23:89-95
   PubMed Web of Science ®Google Scholar
• The GKH, Bleijenberg G, van der Meer JWM. The effect of acclydine in chronic fatigue syndrome: a randomized controlled trial. PLoS Clin Trials 2007;2:e19
   Google Scholar
• McDermott C, Richards SCM, Thomas PW, A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. QJM 2006;99:461-8
   PubMed Web of Science ®Google Scholar
• Bergman M, Huikko S, Huovinen P, et al.; Finnish Study Group for Antimicrobial R. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006;50:3646-50
   PubMed Web of Science ®Google Scholar
• Rawson KM, Rickards H, Hague S, Ward C. Pharmacological treatments for chronic fatigue syndrome in adults. (Protocol) Cochrane Database Syst Rev 2007;(4):CD006813. doi: 10.1002/14651858.CD006813
   Google Scholar
• Zhang W, Liu ZS, Wu Taixiang, Peng WN. Acupuncture for chronic fatigue syndrome. (Protocol) Cochrane Database of Syst Rev 2006;(2):CD006010. doi: 10.1002/14651858.CD006010
   Google Scholar
• Adams D, Wu T, Tai S, Traditional Chinese medicinal herbs for idiopathic chronic fatigue and chronic fatigue syndrome. (Protocol) Cochrane Database Syst Rev 2007;(1):CD006348. doi: 10.1002/14651858.CD006348
   Google Scholar
• Kerr JR, Christian P, Hodgetts A, Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments. J Clin Pathol 2007;60:113-6
   PubMed Web of Science ®Google Scholar
• Tomoda A, Joudoi T, Rabab el-M, Cytokine production and modulation: comparison of patients with chronic fatigue syndrome and normal controls. Psychiatry Res 2005;134:101-4
   PubMedGoogle Scholar
• Fluge Ø, Mella O. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol 2009;1:28
   Google Scholar
• Lyle N, Gomes A, Sur T, The role of antioxidant properties of Nardostachys jatamansi in alleviation of the symptoms of the chronic fatigue syndrome. Behav Brain Res 2009;202:285-90
   PubMedGoogle Scholar
• Kuo YH, Tsai WJ, Loke SH, stragalus membranaceus flavonoids (AMF) ameliorate chronic fatigue syndrome induced by food intake restriction plus forced swimming. J Ethnopharmacol 2009;122:28-34
   PubMed Web of Science ®Google Scholar
• Staines DR, Brenu EW, Marshall-Gradisnik S. Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment? Neuropsychiatr Dis Treat 2009;5:81-9
   PubMed Web of Science ®Google Scholar
• Maes M, Leunis JC. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett 2008;29:902-10
   PubMed Web of Science ®Google Scholar
• Nijs J, Frémont M. Intracellular immune dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: state of the art and therapeutic implications. Expert Opin Ther Targets 2008;12:281-9
   PubMed Web of Science ®Google Scholar
• Lombardi VC, Ruscetti FW, Das Gupta J, Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009;326:585-9
   PubMed Web of Science ®Google Scholar
• Van Houdenhove B, Van Den Eede F, Luyten P. Does hypothalamic-pituitary-adrenal hypofunction in chronic fatigue syndrome reflect a ‘crash’ in the stress system? Med Hypotheses 2009;72:701-5
   PubMed Web of Science ®Google Scholar
• Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009;23(Suppl 2):27-34
   PubMedGoogle Scholar
• McEwen BS, Chatterji S, Diamond DM, The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutaminergic modulation. Mol Psychiatry 2009: published online 25 August 2009, doi: 10.1038/mp.2009.80
   Google Scholar
• Chambers D, Bagnall AM, Hempel S, Forbes C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med 2006;99:506-20
   PubMed Web of Science ®Google Scholar
• Jason LA, Corradi K, Torres-Harding S, Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev 2005;15:29-58
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Available from: http://guidance.nice.org.uk/CG53
   Google Scholar
• Reid SF, Chalder T, Cleare A, Chronic fatigue syndrome. Clin Evid (Online) 2008;pii:1101
   Google Scholar
• Van Houdenhove B. What is the aim of cognitive behavior therapy in chronic fatigue syndrome? Psychother Psychosom 2006; 75:396-7
   PubMed Web of Science ®Google Scholar
• Young JL, Redmond JC. Fibromyalgia, chronic fatigue, and adult attention deficit hyperactivity disorder in the adult: a case study. Psychopharmacol Bull 2007;40:118-26
   PubMedGoogle Scholar
• Rao SG. Current progress in the pharmacological therapy of fibromyalgia. Expert Opin Invest Drugs 2009;18:1479-93
   PubMed Web of Science ®Google Scholar
• Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003; 64(Suppl 14):6-17
   Google Scholar
• Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res 2006;40:370-3
   PubMed Web of Science ®Google Scholar
• Boneva RS, Lin JM, Maloney EM, Use of medications by people with chronic fatigue syndrome and healthy persons: a population-based study of fatiguing illness in Georgia. Health Qual Life Outcomes 2009;7:67
   PubMed Web of Science ®Google Scholar
• Morin CM, Vallières A, Guay B, Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 2009;301:2005-15
   PubMed Web of Science ®Google Scholar
• Nijs J, Paul Wallman K. Chronic fatigue syndrome: an approach combining self-management with graded exercise to avoid exacerbations. J Rehabil Med 2008;40:241-7
   PubMed Web of Science ®Google Scholar
• Van Houdenhove B, Luyten P. Treatment of chronic fatigue syndrome: How to find a ‘new equilibrium’? Patient Educ Couns 2009;77:153-4
   PubMedGoogle Scholar